Published in J Virol on July 01, 2002
Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med (2003) 10.20
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A (2003) 8.21
Genomic analysis of the host response to hepatitis C virus infection. Proc Natl Acad Sci U S A (2002) 5.28
Current and future therapies for hepatitis C virus infection. N Engl J Med (2013) 4.25
Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc Natl Acad Sci U S A (2007) 4.05
Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J Virol (2007) 3.57
Human apolipoprotein e is required for infectivity and production of hepatitis C virus in cell culture. J Virol (2007) 3.18
Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J Virol (2003) 3.10
Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol (2006) 2.88
Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol (2005) 2.85
Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J Virol (2006) 2.68
Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. J Virol (2006) 2.65
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med (2013) 2.63
Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol (2003) 2.60
Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122. J Virol (2010) 2.51
Dengue virus-induced autophagy regulates lipid metabolism. Cell Host Microbe (2010) 2.49
Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology (2009) 2.13
Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab (2009) 2.05
Biochemical and morphological properties of hepatitis C virus particles and determination of their lipidome. J Biol Chem (2010) 2.05
Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. J Virol (2009) 2.00
The molecular and structural basis of advanced antiviral therapy for hepatitis C virus infection. Nat Rev Microbiol (2013) 1.88
An in vitro model of hepatitis C virion production. Proc Natl Acad Sci U S A (2005) 1.86
High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein. J Virol (2007) 1.73
Apolipoprotein E on hepatitis C virion facilitates infection through interaction with low-density lipoprotein receptor. Virology (2009) 1.72
Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. J Virol (2007) 1.68
Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol (2010) 1.67
RNA interference and single particle tracking analysis of hepatitis C virus endocytosis. PLoS Pathog (2009) 1.65
Ultrastructural and biophysical characterization of hepatitis C virus particles produced in cell culture. J Virol (2010) 1.64
Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J Virol (2010) 1.63
Studying hepatitis C virus: making the best of a bad virus. J Virol (2007) 1.62
Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology (2010) 1.59
Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Pathog (2009) 1.56
Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus. PLoS Pathog (2007) 1.56
Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. J Virol (2008) 1.48
Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. PLoS Pathog (2010) 1.45
Hepatitis C virus: assembly and release of virus particles. J Biol Chem (2010) 1.42
Molecular determinants and dynamics of hepatitis C virus secretion. PLoS Pathog (2012) 1.41
Preferential association of Hepatitis C virus with apolipoprotein B48-containing lipoproteins. J Gen Virol (2006) 1.39
Infectivity of hepatitis C virus is influenced by association with apolipoprotein E isoforms. J Virol (2010) 1.39
Metabolic and cardiovascular risk profiles and hepatitis C virus infection in rural Egypt. Gut (2006) 1.34
Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J Virol (2007) 1.33
Secretion of hepatitis C virus envelope glycoproteins depends on assembly of apolipoprotein B positive lipoproteins. PLoS One (2009) 1.31
Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J Virol (2010) 1.31
Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol (2004) 1.29
Hepatitis C virus attachment mediated by apolipoprotein E binding to cell surface heparan sulfate. J Virol (2012) 1.28
Current progress in development of hepatitis C virus vaccines. Nat Med (2013) 1.28
Unique ties between hepatitis C virus replication and intracellular lipids. Trends Endocrinol Metab (2011) 1.27
Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. J Virol (2012) 1.24
Apolipoprotein c1 association with hepatitis C virus. J Virol (2008) 1.24
Multifaceted roles for lipids in viral infection. Trends Microbiol (2011) 1.22
hepatitis c Virus p7 is critical for capsid assembly and envelopment. PLoS Pathog (2013) 1.20
Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission. J Virol (2013) 1.20
Lipids and HCV. Semin Immunopathol (2012) 1.19
A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathog (2010) 1.16
Hepatitis C virus: virology and life cycle. Clin Mol Hepatol (2013) 1.15
Virion assembly and release. Curr Top Microbiol Immunol (2013) 1.15
Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line. J Virol (2009) 1.14
Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles. J Biol Chem (2009) 1.14
Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. J Virol (2009) 1.13
Associations between serum lipids and hepatitis C antiviral treatment efficacy. Hepatology (2010) 1.13
MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells. J Virol (2013) 1.12
Hepatitis C virus, cholesterol and lipoproteins--impact for the viral life cycle and pathogenesis of liver disease. Viruses (2013) 1.12
Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection. Gut (2005) 1.11
Potential cellular receptors involved in hepatitis C virus entry into cells. Lipids Health Dis (2005) 1.10
Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol (2006) 1.09
Characterization of the genome and structural proteins of hepatitis C virus resolved from infected human liver. J Gen Virol (2004) 1.08
Role of lipids in virus replication. Cold Spring Harb Perspect Biol (2011) 1.08
MAP-kinase regulated cytosolic phospholipase A2 activity is essential for production of infectious hepatitis C virus particles. PLoS Pathog (2012) 1.07
Expanding roles for lipid droplets. Curr Biol (2015) 1.06
Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes. Hepatology (2011) 1.06
Human apolipoprotein E peptides inhibit hepatitis C virus entry by blocking virus binding. Hepatology (2012) 1.06
Characterization of hepatitis C RNA-containing particles from human liver by density and size. J Gen Virol (2008) 1.03
Expression of hepatitis C virus proteins in epithelial intestinal cells in vivo. J Gen Virol (2004) 1.03
Primary hepatocytes as targets for hepatitis C virus replication. J Viral Hepat (2008) 1.03
Neutralizing antibody response to hepatitis C virus. Viruses (2011) 1.03
Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps. J Biol Chem (2012) 1.03
Protein kinase D negatively regulates hepatitis C virus secretion through phosphorylation of oxysterol-binding protein and ceramide transfer protein. J Biol Chem (2011) 1.02
Hepatitis C Virus entry: the early steps in the viral replication cycle. Virol J (2009) 1.01
Dengue virus- and hepatitis C virus-induced replication and assembly compartments: the enemy inside--caught in the web. J Virol (2014) 0.99
Pathogenesis of hepatitis E virus and hepatitis C virus in chimpanzees: similarities and differences. J Virol (2010) 0.99
Role for ADP ribosylation factor 1 in the regulation of hepatitis C virus replication. J Virol (2010) 0.97
Engrafted human stem cell-derived hepatocytes establish an infectious HCV murine model. J Clin Invest (2014) 0.97
Role for TBC1D20 and Rab1 in hepatitis C virus replication via interaction with lipid droplet-bound nonstructural protein 5A. J Virol (2012) 0.97
Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. J Hepatol (2011) 0.97
Lipid metabolism and HCV infection. Viruses (2010) 0.96
NS3 Peptide, a novel potent hepatitis C virus NS3 helicase inhibitor: its mechanism of action and antiviral activity in the replicon system. Antimicrob Agents Chemother (2007) 0.94
The rate of hepatitis C virus infection initiation in vitro is directly related to particle density. Virology (2010) 0.94
Amphipathic α-helices in apolipoproteins are crucial to the formation of infectious hepatitis C virus particles. PLoS Pathog (2014) 0.93
The association of hepatitis C virus glycoproteins with apolipoproteins E and B early in assembly is conserved in lipoviral particles. J Biol Chem (2014) 0.93
Hepatitis C virus evasion mechanisms from neutralizing antibodies. Viruses (2011) 0.93
Targeting host factors: a novel rationale for the management of hepatitis C virus. World J Gastroenterol (2009) 0.93
Exploitation of lipid components by viral and host proteins for hepatitis C virus infection. Front Microbiol (2012) 0.92
Unfolded protein response in hepatitis C virus infection. Front Microbiol (2014) 0.92
The role of humoral innate immunity in hepatitis C virus infection. Viruses (2012) 0.91
Hepatitis C virus life cycle and lipid metabolism. Biology (Basel) (2014) 0.91
Host-Targeting Agents to Prevent and Cure Hepatitis C Virus Infection. Viruses (2015) 0.91
Three different functional microdomains in the hepatitis C virus hypervariable region 1 (HVR1) mediate entry and immune evasion. J Biol Chem (2012) 0.91
New perspectives for preventing hepatitis C virus liver graft infection. Lancet Infect Dis (2016) 0.91
Hepatitis C virus induced insulin resistance impairs response to anti viral therapy. World J Gastroenterol (2012) 0.90
The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. Front Immunol (2014) 0.89
Binding of hepatitis C virus to CD81. Science (1998) 12.40
Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A (1999) 6.05
Recycling receptors: the round-trip itinerary of migrant membrane proteins. Cell (1983) 5.99
Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A (1996) 4.82
Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol (1993) 4.13
Hepatitis C: the clinical spectrum of disease. Hepatology (1997) 3.94
Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A (1997) 3.88
Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol (1992) 3.59
Purification of the low density lipoprotein receptor, an acidic glycoprotein of 164,000 molecular weight. J Biol Chem (1982) 3.22
A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2. J Virol (1998) 3.13
Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J Virol (2000) 2.50
Density heterogeneities of hepatitis C virus in human sera due to the binding of beta-lipoproteins and immunoglobulins. Med Microbiol Immunol (1993) 2.36
Structure-function analysis of hepatitis C virus envelope-CD81 binding. J Virol (2000) 2.32
Hepatitis C virus glycoprotein complex localization in the endoplasmic reticulum involves a determinant for retention and not retrieval. J Biol Chem (1998) 2.14
Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins. J Viral Hepat (1996) 1.94
Hepatitis C virus: buoyant density of the factor VIII-derived isolate in sucrose. J Med Virol (1991) 1.93
Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients. J Virol (2001) 1.84
The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding. J Biol Chem (1983) 1.67
Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. J Gen Virol (2000) 1.65
Quantitation of HCV RNA using real-time PCR and fluorimetry. J Virol Methods (2001) 1.62
Specific incorporation of host cell surface proteins into budding vesicular stomatitis virus particles. Cell (1980) 1.61
Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. Hepatology (1999) 1.60
Extraordinarily low density of hepatitis C virus estimated by sucrose density gradient centrifugation and the polymerase chain reaction. J Gen Virol (1992) 1.56
Cell fusion activity of hepatitis C virus envelope proteins. J Virol (2000) 1.50
Sensitization to Fas-mediated apoptosis by hepatitis C virus core protein. Virology (1997) 1.49
The use of monoclonal antibodies to localize the low density lipoprotein receptor-binding domain of apolipoprotein B. J Biol Chem (1989) 1.41
Association of hepatitis C virus particles with immunoglobulin: a mechanism for persistent infection. J Gen Virol (1995) 1.36
Density analysis of hepatitis C virus particle population in the circulation of infected hosts: implications for virus neutralization or persistence. J Hepatol (1995) 1.36
Heterozygous familial hypercholesterolemia: failure of normal allele to compensate for mutant allele at a regulated genetic locus. Cell (1976) 1.31
Buoyant density of hepatitis C virus recovered from infected hosts: two different features in sucrose equilibrium density-gradient centrifugation related to degree of liver inflammation. Hepatology (1994) 1.30
Automated quantitative determination of hepatitis C virus viremia by reverse transcription-PCR. J Clin Microbiol (1994) 1.29
Binding of human lipoproteins (low, very low, high density lipoproteins) to recombinant envelope proteins of hepatitis C virus. Med Microbiol Immunol (2000) 1.22
Assembly of very low density lipoprotein: a two-step process of apolipoprotein B core lipidation. J Nutr (1999) 1.09
Hepatitis C virus core particle detected by immunoelectron microscopy and optical rotation technique. Hepatol Res (2001) 1.08
Apolipoprotein B in the rough endoplasmic reticulum: translation, translocation and the initiation of lipoprotein assembly. J Nutr (1999) 1.04
HCV core immunodominant region analysis using mouse monoclonal antibodies and human sera: characterization of major epitopes useful for antigen detection. J Med Virol (1998) 0.99
Examination of the buoyant density of hepatitis C virus by the polymerase chain reaction. J Virol Methods (1992) 0.97
Hepatitis C virus infection and type II cryoglobulinemia: an immunological perspective. Hepatology (1997) 0.96
Suramin blocks hepatitis C binding to human hepatoma cells in vitro. J Med Virol (1999) 0.91
Serial density analysis of hepatitis C virus particle populations in chronic hepatitis C patients treated with interferon-alpha. J Med Virol (1995) 0.87
The ability of suramin to block CD4-gp120 binding is reversed in the presence of albumin. Antimicrob Agents Chemother (1991) 0.85
Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol (2000) 5.26
Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology (2001) 4.28
Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature (1990) 4.10
Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A (1997) 3.88
Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med (1995) 3.41
Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepatol (1992) 3.35
Peg-IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis (2013) 2.99
Hepatitis C virus infection protein network. Mol Syst Biol (2008) 2.91
Structure and cell cycle-regulated transcription of the human cyclin A gene. Proc Natl Acad Sci U S A (1994) 2.69
Cyclin A is required in S phase in normal epithelial cells. Biochem Biophys Res Commun (1992) 2.55
Infection with hepatitis C virus genotype 4 is associated with a poor response to interferon-alpha. Ann Intern Med (2000) 2.43
State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases. Proc Natl Acad Sci U S A (1981) 2.37
Detection of hepatitis B virus sequences in serum by using in vitro enzymatic amplification. J Virol Methods (1988) 2.36
Mice lacking the MHC class II-associated invariant chain. Cell (1993) 2.30
Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N Engl J Med (1985) 2.29
Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. Euro Surveill (2005) 2.20
Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways. Nature (1990) 2.11
Eradication of hepatitis C virus RNA after alpha-interferon therapy. Ann Intern Med (1994) 2.11
Evidence for a viral superantigen in humans. Nature (1992) 2.01
Delayed early embryonic lethality following disruption of the murine cyclin A2 gene. Nat Genet (1997) 2.01
Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology (1995) 2.00
Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The Collaborative Research Group on Multiple Sclerosis. Proc Natl Acad Sci U S A (1997) 1.97
Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut (2000) 1.94
Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol (1998) 1.91
Hepatitis C in a ward for cystic fibrosis and diabetic patients: possible transmission by spring-loaded finger-stick devices for self-monitoring of capillary blood glucose. Infect Control Hosp Epidemiol (2001) 1.88
Expression of hepatitis C virus NS5A natural mutants in a hepatocytic cell line inhibits the antiviral effect of interferon in a PKR-independent manner. Hepatology (2001) 1.84
Hepatitis C virus biology. Cell Death Differ (2003) 1.83
Prevalence of human respiratory viruses in adults with acute respiratory tract infections in Beijing, 2005-2007. Clin Microbiol Infect (2009) 1.76
Hepatitis C virus persistence in human hematopoietic cells injected into SCID mice. Hepatology (1998) 1.74
The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. Aliment Pharmacol Ther (2011) 1.73
Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas. Gut (2005) 1.66
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat (2005) 1.64
Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene (1999) 1.63
Quantitation of HCV RNA using real-time PCR and fluorimetry. J Virol Methods (2001) 1.62
Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. Hepatology (1999) 1.60
Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res (2001) 1.57
Epidemiological and virological analysis of couples infected with hepatitis C virus. Gut (1999) 1.55
An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A (1998) 1.50
AIM2/ASC triggers caspase-8-dependent apoptosis in Francisella-infected caspase-1-deficient macrophages. Cell Death Differ (2012) 1.50
Low prevalence of precore mutations in hepatitis B virus DNA in fulminant hepatitis type B in France. J Hepatol (1993) 1.49
Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest (1992) 1.45
Effect of pregnancy on chronic hepatitis C: a case-control study. Lancet (2000) 1.43
Defective hepatitis B virus particles are generated by packaging and reverse transcription of spliced viral RNAs in vivo. J Virol (1991) 1.41
Impact of TT virus infection in acute and chronic, viral- and non viral-related liver diseases. J Hepatol (2000) 1.40
Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clin Infect Dis (1996) 1.39
Triggering of acute alcoholic hepatitis by alpha-interferon therapy. J Hepatol (1999) 1.39
Liver-related mortality in human-immunodeficiency-virus-infected patients between 1995 and 2003 in the French GERMIVIC Joint Study Group Network (MORTAVIC 2003 Study). J Viral Hepat (2007) 1.39
The course of hepatitis C virus infection after liver transplantation. Hepatology (1994) 1.38
Evidence that hepatitis B virus has a role in liver-cell carcinoma in alcoholic liver disease. N Engl J Med (1982) 1.37
Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein. J Virol (2001) 1.36
Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology (1993) 1.36
Risk factors for hepatitis C virus transmission to health care workers after occupational exposure: a European case-control study. Clin Infect Dis (2005) 1.35
Oxidation of arsenite to arsenate by a bacterium isolated from an aquatic environment. Biometals (1999) 1.32
A novel PCR technique using Alu-specific primers to identify unknown flanking sequences from the human genome. Genomics (1995) 1.30
A novel gene (HIP) activated in human primary liver cancer. Cancer Res (1992) 1.30
Liver resection and needle liver biopsy cause hematogenous dissemination of liver cells. Hepatology (1999) 1.28
WAKs: cell wall-associated kinases linking the cytoplasm to the extracellular matrix. Plant Mol Biol (2001) 1.27
A novel HLA class II molecule (DR alpha-DQ beta) created by mismatched isotype pairing. Nature (1987) 1.26
Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: a study of a low-endemic area. Hepatology (1993) 1.26
Identification of human cancer-related genes by naturally occurring Hepatitis B Virus DNA tagging. Oncogene (2001) 1.26
Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J Natl Cancer Inst (2000) 1.23
Overexpression of human cyclin A advances entry into S phase. Oncogene (1995) 1.22
Hybrid HLA-DC antigens provide molecular evidence for gene trans-complementation. Nature (1984) 1.19
Oxidized low-density lipoprotein promotes mature dendritic cell transition from differentiating monocyte. J Immunol (2001) 1.17
Phylogeny of a novel family of human endogenous retrovirus sequences, HERV-W, in humans and other primates. AIDS Res Hum Retroviruses (1999) 1.17
Regulation of cell cycle progression by Swe1p and Hog1p following hypertonic stress. Mol Biol Cell (2001) 1.15
Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol (1999) 1.15
Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon). J Gen Virol (1994) 1.15
Specific vaccine therapy in chronic hepatitis B infection. Lancet (1994) 1.15
Comparative analysis of two assays for genotyping hepatitis C virus based on genotype-specific primers or probes. J Hepatol (1995) 1.14
In vivo and in vitro expression of defective hepatitis B virus particles generated by spliced hepatitis B virus RNA. Hepatology (1995) 1.13
The grey mouse lemur: a non-human primate model for ageing studies. Ageing Res Rev (2011) 1.13
The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B. Aliment Pharmacol Ther (2008) 1.13
Frequent and early in utero HIV-1 infection. AIDS Res Hum Retroviruses (1991) 1.13
Molecular cloning and characterization of MSRV-related sequences associated with retrovirus-like particles. Virology (1999) 1.12
Association between HCV and HBV infection in hepatocellular carcinoma and alcoholic liver disease. J Hepatol (1991) 1.11
Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, 2004. Euro Surveill (2008) 1.11
Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa. Gastroenterology (1997) 1.10
Comparative distribution of mRNA encoding the growth hormone secretagogue-receptor (GHS-R) in Microcebus murinus (Primate, lemurian) and rat forebrain and pituitary. J Comp Neurol (2001) 1.10
Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome. Oncogene (1998) 1.10
Modification of cyclin A expression by hepatitis B virus DNA integration in a hepatocellular carcinoma. Oncogene (1992) 1.10
Direct association and nuclear import of the hepatitis B virus X protein with the NF-kappaB inhibitor IkappaBalpha. Mol Cell Biol (1999) 1.09
Partial nucleotide sequence analysis of a French hepatitis C virus: implications for HCV genetic variability in the E2/NS1 protein. J Gen Virol (1991) 1.08
Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol (2001) 1.08
Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status. J Viral Hepat (2006) 1.06
Immunohistochemical evidence for human immunodeficiency virus-1 infection of liver Kupffer cells. Hum Pathol (1990) 1.06
Efficiency of Ber-EP4 antibody for isolating circulating epithelial tumor cells before RT-PCR detection. Am J Clin Pathol (1999) 1.05